Clinical Trial Update: Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating SAR245409 in combination with rituximab or bendamustine plus rituximab in patients with indolent non-Hodgkin lymphoma, mantle cell ly…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Indolent Non-hodgkin Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Rituximab (rituximab)
• SAR245409

Snippet

Sponsor: Sanofi | Conditions: Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma | Phase 1 | Status: COMPLETED